Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Indvirkning af en ketogen diæt på metabolisk og psykiatrisk sundhed hos patienter med bipolar eller skizofreni sygdom

10. november 2026 opdateret af: Shebani Sethi, Stanford University

Indvirkningen af ​​en ketogen diæt med lavt kulhydratindhold, højt fedtindhold på fedme, metaboliske abnormiteter og psykiatriske symptomer hos patienter med bipolar eller skizofrenisygdom: Et pilotforsøg

To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with either schizophrenia or bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or are currently taking psychotropic medications experiencing metabolic side effects.

Studieoversigt

Detaljeret beskrivelse

Adults with mental illness represent a high-risk, marginalized group in the current metabolic and obesity epidemic. Among US adults with severe mental illness, metabolic syndrome are highly prevalent conditions having severe consequences, with patients estimated to die on average 25 years earlier than the general population largely of premature cardiovascular disease. Many psychiatric medications, particularly neuroleptics and mood stabilizers, may, in addition, contribute to metabolic side effects and weight gain. Low-carbohydrate high-fat (LCHF) or ketogenic diets (KD) have been shown to reduce cardiovascular risk in those with insulin resistance. Recent findings support the idea that bipolar disorder, along with other psychiatric diseases schizophrenia, may have roots of metabolic dysfunction: cerebral glucose hypometabolism, oxidative stress, as well as mitochondrial and neurotransmitter dysfunction which has downstream effects on synapse connections. A KD diet provides alternative fuel to the brain aside from glucose and is believed to contain beneficial neuroprotective effects, including stabilization of brain networks, reduction of inflammation and oxidative stress. The purpose of this study is to evaluate both the metabolic and psychiatric outcomes with a KD diet in this psychiatric population.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

23

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Stanford, California, Forenede Stater, 94305
        • Stanford University Department of Psychiatry & Behavioral Sciences

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age 18-75 years old
  2. Meet DSM V criteria for schizophrenia or bipolar disorder, any subtype, for > 1 year and clinically stable (with no hospitalization for past 3 months)
  3. Currently taking psychotropic medication and gained at least 5% weight since starting medication or have a BMI greater than or equal to 26 kg/m2 or presence of at least one metabolic abnormality (hypertriglyceridemia, insulin resistance, dyslipidemia, impaired glucose tolerance)
  4. Willing to consent to all study procedures and attend follow-up appointments and motivated to follow the dietary program.
  5. Sufficient control over their food intake to adhere to study diets.
  6. Willingness to regularly monitor blood pressure, glucose, dietary intake, and body weight over the 4-month trial

Exclusion Criteria:

  1. Any subject pregnant or nursing

  2. Comorbidity of developmental delay

  3. Active substance abuse with illicit drugs or alcohol

  4. In a current severe mood or psychotic state when entering the study that would prohibit compliance with study visits or dietary program.

  5. Anyone who has been hospitalized or taken clozapine over the past 3 months

  6. Inability to complete baseline measurements

  7. Severe renal or hepatic insufficiency

  8. Cardiovascular dysfunction, including diagnosis of:

    1. Congestive heart failure
    2. Angina
    3. Arrhythmias
    4. Cardiomyopathy
    5. Valvular heart disease
  9. Any other medical condition that may make either diet dangerous as determined by the study medical team (e.g. anorexia nervosa)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Ketogenic Diet 16 Week Group

Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support

Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in heart rate from baseline
Tidsramme: Baseline, 16 weeks

Heart rate recorded at 9 visits during study

Baseline, 16 weeks
Change in blood pressure from baseline
Tidsramme: Baseline, 16 weeks

Blood pressure recorded at 9 visits during study

Baseline, 16 weeks
Change in weight from baseline
Tidsramme: Baseline, 16 weeks

Weight recorded at 9 visits during study

Baseline, 16 weeks
Change in waist circumference from baseline
Tidsramme: Baseline, 16 weeks

waist circumference measured at 9 visits during study

Baseline, 16 weeks
Change in visceral fat mass from baseline
Tidsramme: Baseline, 16 weeks

Body composition (SECA) recorded at 5 visits during study

Baseline, 16 weeks
Change in body fat mass from baseline
Tidsramme: Baseline, 16 weeks

Body composition (SECA) recorded at 5 visits during study

Baseline, 16 weeks
Percent Change in Hemoglobin A1c from baseline
Tidsramme: Baseline, 16 weeks

Hemoglobin A1c recorded at initial and final visits

Baseline, 16 weeks
Change in insulin resistance measure (HOMA-IR) from baseline
Tidsramme: Baseline, 16 weeks

HOMA-IR measured at initial and final visits

Baseline, 16 weeks
Change in inflammatory marker (hsCRP) from baseline
Tidsramme: Baseline, 16 weeks

hsCRP measured at initial and final visits

Baseline, 16 weeks
Change in lipid profile TG (triglycerides) from baseline
Tidsramme: Baseline, 16 weeks

Lipid profile TG measured at initial and final visits

Baseline, 16 weeks
Change in lipid profile small LDL (small dense LDL) from baseline
Tidsramme: Baseline, 16 weeks

Lipid profile small LDL measured at initial and final visits

Baseline, 16 weeks
Change in lipid profile (HDL) from baseline
Tidsramme: Baseline,16 weeks

Lipid profile HDL measured at initial and final visits

Baseline,16 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Psychiatric Indices - Mood
Tidsramme: Baseline, 16 weeks

Change in Mood Qualitative Score (Clinical Mood Monitoring) from baseline

Baseline, 16 weeks
Psychiatric Indices- Clinical Global Impression
Tidsramme: Baseline, 16 weeks

Change in Clinical Global Impression Scales (CGI) from baseline 1-7 scale. 1= not at all ill, 7= among the most extremely ill patients)

Baseline, 16 weeks
Generalized Anxiety Disorder - GAD-7 Anxiety
Tidsramme: Baseline, 16 weeks

Change in Generalized Anxiety Symptom (GAD-7) scale from baseline. 0-15+ scale. (0= no anxiety, 15+= severe anxiety)

Baseline, 16 weeks
Patient Health Questionnaire - PHQ-9 Depression
Tidsramme: Baseline, 16 weeks

Change in Patient Health Questionnaire (PHQ-9) from baseline. Score range 0-27 (0= no depression, 27= severe depression)

Baseline, 16 weeks
Psychiatric Indices- Global Assessment of Functioning
Tidsramme: Baseline, 16 weeks

Change in Global Assessment of Functioning (GAF) Scale from baseline. 1-100 scale (1= persistent danger of hurting self or others, 100= superior functioning)

Baseline, 16 weeks
Psychiatric Indices- Quality of Life
Tidsramme: Baseline, 16 weeks

Change in Manchester Quality of Life Scale (MANSA) from baseline. Range 12-84 (each of 12 outcomes rated from 1= could not be worse to 7= could not be better; <4= dissatisfied with QoL, >4= satisfied with QoL)

Baseline, 16 weeks
Psychiatric Indices- BPRS
Tidsramme: Baseline, 16 weeks

Change in Brief Psychiatric Rating Scale (BPRS) from baseline. Score range 18-126. (For each of 18 symptoms, 1=symptom not present, 7= extremely severe)

Baseline, 16 weeks
Pittsburgh Sleep Quality Index - PSQI
Tidsramme: Baseline, 16 weeks

Change in Pittsburgh Sleep Quality Index from baseline. 0-21 scale (<5=good sleeper; 5+= meaningfully disturbed sleep or poor sleeper)

Baseline, 16 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Shebani Sethi, MD, Stanford University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. februar 2019

Primær færdiggørelse (Faktiske)

11. august 2022

Studieafslutning (Faktiske)

11. august 2022

Datoer for studieregistrering

Først indsendt

30. april 2019

Først indsendt, der opfyldte QC-kriterier

30. april 2019

Først opslået (Faktiske)

2. maj 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. december 2024

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner